Adams-Chapman, IraWatterberg, Kristi L.Nolen, Tracy L.Hirsch, ShawnCole, Carol A.Cotten, C. MichaelOh, WilliamPoindexter, Brenda B.Zaterka-Baxter, Kristin M.Das, AbhikBackstrom Lacy, ConraScorsone, Ann MarieDuncan, Andrea F.DeMauro, Sara B.Goldstein, Ricki F.Colaizy, Tarah T.Wilson-Costello, Deanne E.Purdy, Isabell B.Hintz, Susan R.Heyne, Roy J.Myers, Gary J.Fuller, JanellMerhar, StephanieHarmon, Heidi M.Peralta-Carcelen, MyriamKilbride, Howard W.Maitre, Nathalie L.Vohr, Betty R.Natarajan, GirijaMintz-Hittner, HelenQuinn, Graham E.Wallace, David K.Olson, Richard J.Orge, Faruk H.Tsui, IrenaGaynon, MichaelHutchinson, Amy K.He, Yu-GuangWinter, Timothy W.Yang, Michael B.Haider, Kathryn M.Cogen, Martin S.Hug, DeniseBremer, Don L.Donahue, John P.Lucas, William R.Phelps, Dale L.Higgins, Rosemary D.Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network2023-08-112023-08-112021Adams-Chapman I, Watterberg KL, Nolen TL, et al. Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial. J Perinatol. 2021;41(8):2072-2087. doi:10.1038/s41372-021-01018-5https://hdl.handle.net/1805/34862Objective: This study evaluates the 24-month follow-up for the NICHD Neonatal Research Network (NRN) Inositol for Retinopathy Trial. Study design: Bayley Scales of Infants Development-III and a standardized neurosensory examination were performed in infants enrolled in the main trial. Moderate/severe NDI was defined as BSID-III Cognitive or Motor composite score <85, moderate or severe cerebral palsy, blindness, or hearing loss that prevents communication despite amplification were assessed. Results: Primary outcome was determined for 605/638 (95%). The mean gestational age was 25.8 ± 1.3 weeks and mean birthweight was 805 ± 192 g. Treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe NDI (60% vs 56%, p = 0.40). Conclusions: Treatment group did not affect the risk of death or survival with moderate/severe NDI. Despite early termination, this study represents the largest RCT of extremely preterm infants treated with myo-inositol with neurodevelopmental outcome data.en-USPublisher PolicyCerebral PalsyChild developmentGestational ageExtremely premature infantInositolArticle